Tolerability, Pharmacokinetics and Antiviral Activity of Rhsa/ifnα2a for the Treatment of Chronic Hepatitis B Infection.
Yanhua Ding,Jinfeng Lou,Hong Chen,Xiaojiao Li,Min Wu,Cuiyun Li,Jingrui Liu,Chengjiao Liu,Qingmei Li,Hong Zhang,Junqi Niu
DOI: https://doi.org/10.1111/bcp.13184
2016-01-01
Abstract:AimsA recombinant human serum albumin‐interferon alpha2a fusion protein (rHSA/IFNα2a) is expected to extend the half‐life of IFNα2a. This study aims to evaluate the tolerability, safety and efficacy of rHSA/IFNα2a.MethodsThis is an open, randomized, positive control, multiple‐dose ascending Phase Ib study. A panel of 32 treatment naïve and non‐cirrhotic chronic hepatitis B patients were divided into four cohorts, and each received 600, 750 or 900 μg of rHSA/IFNα2a or 180 μg of PEG‐IFNα2a for 3 months. Tolerability, pharmacokinetics and antiviral responses were assessed.ResultsThirty‐one of 32 enrolled patients completed the treatment study. The rHSA/IFNα2a treatment was better tolerated than the PEG‐IFNα2a 180 μg treatment, as evidenced by blood cell counts and higher serum albumin levels. Half‐life (t1/2) of rHSA/IFNα2a was estimated to be 120–140 h, and is potentially suitable for a dosing interval of 2 weeks or longer. Pharmacokinetics of the last dose between rHSA/IFNα2a 750 μg and PEG‐IFNα2a 180 μg, with the exception of t1/2, was comparable, and a similar kinetics of inhibiting HBV DNA replication was observed in both groups. Mean reductions in serum HBV DNA levels after treatment were −1.32, −2.13, −1.10 and −2.48 log10 IU/ml in the 600, 750 and 900 μg rHSA/IFNα2a groups and PEG‐IFNα2a group, respectively.ConclusionsThe rHSA/IFNα2a treatment was well tolerated and can be administered biweekly. Similar efficacy in inhibiting HBV replication was observed in both PEG‐IFNα2a and rHSA/IFNα2a 750 μg groups.